Cencora, Inc. (NYSE:COR) Chairman Sells $5,071,822.20 in Stock

Cencora, Inc. (NYSE:COR - Get Free Report) Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the transaction, the chairman now owns 285,088 shares in the company, valued at approximately $67,223,750.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Cencora Stock Up 0.1 %

Shares of NYSE:COR traded up $0.35 during trading on Wednesday, reaching $234.52. 754,869 shares of the stock were exchanged, compared to its average volume of 1,415,712. Cencora, Inc. has a 1-year low of $182.75 and a 1-year high of $247.66. The stock has a fifty day moving average of $232.32 and a two-hundred day moving average of $230.85. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55. The firm has a market cap of $46.78 billion, a price-to-earnings ratio of 25.62, a price-to-earnings-growth ratio of 1.40 and a beta of 0.44.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, topping the consensus estimate of $3.18 by $0.16. The firm had revenue of $74.20 billion for the quarter, compared to the consensus estimate of $73.32 billion. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The business's revenue was up 10.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.92 earnings per share. Research analysts anticipate that Cencora, Inc. will post 13.63 earnings per share for the current fiscal year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 9th were issued a dividend of $0.51 per share. This represents a $2.04 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date was Friday, August 9th. Cencora's dividend payout ratio is currently 22.32%.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on COR. StockNews.com downgraded Cencora from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 20th. Leerink Partners reduced their price objective on shares of Cencora from $277.00 to $275.00 and set an "outperform" rating on the stock in a research note on Monday, October 7th. Robert W. Baird lowered their target price on Cencora from $287.00 to $283.00 and set an "outperform" rating for the company in a research report on Friday, September 6th. JPMorgan Chase & Co. increased their target price on shares of Cencora from $280.00 to $287.00 and gave the company an "overweight" rating in a research report on Wednesday, August 21st. Finally, Evercore ISI decreased their price target on Cencora from $270.00 to $250.00 and set an "outperform" rating for the company in a report on Tuesday, October 8th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $259.44.

Institutional Trading of Cencora

Institutional investors and hedge funds have recently modified their holdings of the stock. Financial Advocates Investment Management boosted its holdings in Cencora by 4.7% during the second quarter. Financial Advocates Investment Management now owns 978 shares of the company's stock worth $220,000 after purchasing an additional 44 shares during the last quarter. Checchi Capital Advisers LLC grew its holdings in shares of Cencora by 2.2% in the second quarter. Checchi Capital Advisers LLC now owns 2,217 shares of the company's stock valued at $499,000 after acquiring an additional 48 shares in the last quarter. Valeo Financial Advisors LLC increased its position in shares of Cencora by 3.4% during the second quarter. Valeo Financial Advisors LLC now owns 1,566 shares of the company's stock valued at $353,000 after acquiring an additional 51 shares during the last quarter. Impact Partnership Wealth LLC lifted its holdings in Cencora by 2.6% during the third quarter. Impact Partnership Wealth LLC now owns 2,042 shares of the company's stock worth $460,000 after acquiring an additional 51 shares during the period. Finally, Evergreen Capital Management LLC boosted its position in Cencora by 4.7% in the second quarter. Evergreen Capital Management LLC now owns 1,147 shares of the company's stock worth $258,000 after purchasing an additional 52 shares during the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.